Saiki Masafumi, Ohyanagi Fumiyoshi, Ariyasu Ryo, Koyama Junji, Sonoda Tomoaki, Nishikawa Shingo, Kitazono Satoru, Yanagitani Noriko, Horiike Atsushi, Ninomiya Hironori, Ishikawa Yuichi, Nishio Makoto
Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo.
Division of Pulmonary Medicine, Clinical Department of Internal Medicine, Jichi Medical University Saitama Medical Center, Saitama.
Jpn J Clin Oncol. 2017 Dec 1;47(12):1189-1192. doi: 10.1093/jjco/hyx133.
Inflammatory myofibroblastic tumor (IMT) is a neoplasm characterized by the proliferaton of myofibroblasts with the infiltration of inflammatory cells. There is no standard treatment for patients with recurrent or metastatic IMT. We describe here a patient with hyper-progressive IMT with an anaplastic lymphoma kinase (ALK) fusion gene that dramatically responded to alectinib without adverse events. His dramatic and enduring response supports the observation that alectinib may be considered a good treatment option for rare aggressive ALK-positive tumors.
炎性肌纤维母细胞瘤（IMT）是一种以肌成纤维细胞增殖并伴有炎性细胞浸润为特征的肿瘤。对于复发或转移性IMT患者，尚无标准治疗方法。我们在此描述一名患有超进展性IMT且携带间变性淋巴瘤激酶（ALK）融合基因的患者，该患者对阿来替尼产生了显著反应且无不良事件发生。他的显著且持久的反应支持了以下观点，即阿来替尼可被视为罕见侵袭性ALK阳性肿瘤的一种良好治疗选择。
